FOLR1 overexpression
|
Ovarian Cancer
|
FOLR1 overexpression
|
Ovarian Cancer
|
IMGN 853 Sensitive: B - Late Trials
Immunogen Press Release - 5 days (NewB)
|
IMGN 853 Sensitive: B - Late Trials
Immunogen Press Release - 5 days - (New B)
|
FOLR1 overexpression
|
Ovarian Cancer
|
FOLR1 overexpression
|
Ovarian Cancer
|
PARP inhibitor Resistant: C3 – Early Trials
|
PARP inhibitor Resistant: C3 – Early Trials
|
FOLR1 overexpression
|
Gastric Cancer
|
FOLR1 overexpression
|
Gastric Cancer
|
bevacizumab + IMGN 853 Sensitive: C3 – Early Trials
|
bevacizumab + IMGN 853 Sensitive: C3 – Early Trials
|
FOLR1 overexpression
|
Ovarian Cancer
|
FOLR1 overexpression
|
Ovarian Cancer
|
bevacizumab + IMGN 853 Sensitive: C3 – Early Trials
|
bevacizumab + IMGN 853 Sensitive: C3 – Early Trials
|
FOLR1 overexpression
|
Ovarian Cancer
|
FOLR1 overexpression
|
Ovarian Cancer
|
CT900 Sensitive: C3 – Early Trials
|
CT900 Sensitive: C3 – Early Trials
|
FOLR1 overexpression
|
Ovarian Cancer
|
FOLR1 overexpression
|
Ovarian Cancer
|
IMGN151 Sensitive: D – Preclinical
|
IMGN151 Sensitive: D – Preclinical
|